文献速递胸部肿瘤

奥希替尼一线治疗EGFR突变阳性晚期非小细胞肺癌

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2017-08-25

AURA研究纳入60例初治EGFR突变晚期非小细胞肺癌患者,分80mg与160mg两组各30例接受奥希替尼治疗。总客观缓解率77%,中位无进展生存期20.5个月;进展后血浆中未检出获得性EGFR T790M突变。

要点

  • 奥希替尼一线治疗初治EGFR突变晚期NSCLC总ORR为77%,中位PFS为20.5个月。
  • 80mg组ORR 67%、中位PFS 22.1个月;160mg组ORR 87%、中位PFS 19.3个月。
  • 38例进展后血浆样本中50%未检出循环肿瘤DNA,未检出获得性EGFR T790M。

核心结论

  • 奥希替尼在初治EGFR突变晚期非小细胞肺癌患者中显示出稳健的客观缓解率和延长的无进展生存期,进展后血浆样本中无获得性EGFR T790M突变证据。

研究设计与样本

  • AURA研究(ClinicalTrials.gov标识NCT01802632)包含两个初治患者队列,评估奥希替尼一线治疗EGFR突变晚期非小细胞肺癌的临床活性和安全性。
  • 60例初治局部晚期或转移性EGFR突变非小细胞肺癌患者接受奥希替尼80mg或160mg每日一次(每队列30例)。
  • 终点包括研究者评估的客观缓解率、无进展生存期和安全性评价,并在疾病进展后收集血浆样本探讨耐药机制。

主要发现

  • 数据截止2016年11月1日,中位随访19.1个月。
  • 总ORR在80mg组为67%(95%CI 47%至83%),160mg组为87%(95%CI 69%至96%),跨剂量合计为77%(95%CI 64%至87%)。
  • 中位PFS在80mg组为22.1个月(95%CI 13.7至30.2个月),160mg组为19.3个月(95%CI 13.7至26.0个月),跨剂量合计为20.5个月(95%CI 15.0至26.1个月)。
  • 38例有进展后血浆样本的患者中,50%未检出循环肿瘤DNA;19例可评估患者中9例存在推定的耐药机制,包括MET扩增(n=1)、EGFR和KRAS扩增(n=1)、MEK1、KRAS或PIK3CA突变(各n=1)、EGFR C797S突变(n=2)、JAK2突变(n=1)和HER2外显子20插入(n=1)。
  • 未检出获得性EGFR T790M突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Patients and Methods Sixty treatment-naïve patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort). End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation. Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms. Results At data cutoff (November 1, 2016), median follow-up was 19.1 months. Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses. Median PFS time was 22.1 months (95% CI, 13.7 to 30.2 months) in the 80-mg group, 19.3 months (95% CI, 13.7 to 26.0 months) in the 160-mg group, and 20.5 months (95% CI, 15.0 to 26.1 months) across doses. Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA. Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1). Acquired EGFR T790M was not detected. Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-naïve patients with EGFRm advanced NSCLC. There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2017. PMID: 28841389. doi:10.1200/JCO.2017.74.7576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。